Allergan Presents Data From 21 Abstracts At The 2017 American Academy Of Dermatology Meeting In Orlando, FL

DUBLIN, March 3, 2017 /PRNewswire/ -- Allergan plc, (NYSE: AGN), a leading global pharmaceutical company, announced today that it will present 21 Allergan-supported abstracts, a record high for the brand, at the 2017 Annual American Academy of Dermatology (AAD) meeting in Orlando, Florida from March 3-7, 2017.

The scheduled times (noted in local Eastern Time) of the 21 Allergan presentations, presentation titles, locations and authors are as follows: 

Efficacy and Safety of OnabotulinumtoxinA for Moderate to Severe Forehead Lines in Subjects With Upper Facial Lines

• Date and Time: Friday, March 3, 1:35-1:40 PM
• Location: E-Poster, Aesthetic Dermatology Section
• Authors: Koen De Boulle, Philip Werschler, Michael H. Gold, Suzanne Bruce, Gerhard Sattler, Patricia Ogilvie, Cheri Mao, Domenico Vitarella, Xiaofang Lei, Bhushan Hardas

Efficacy and Safety of OnabotulinumtoxinA for Treatment of Moderate to Severe Forehead Lines

• Date and Time: Friday, March 3, 1:40-1:45 PM
• Location: E-Poster, Aesthetic Dermatology Section
• Authors: Steve Fagien, Joel L. Cohen, William Coleman, Gary Monheit, Jean Carruthers, Cheri Mao, Domenico Vitarella, Xiaofang Lei, Bhushan Hardas

OnabotulinumtoxinA (BOTOX^®) Displays Superior Activity to IncobotulinumtoxinA Drug Product (XEOMIN^®) in Multiple In Vitro and In Vivo Assays

• Date and Time: Friday, March 3, 2:45-2:50 PM
• Location: E-Poster, Aesthetic Dermatology Section
• Authors: David Canty, Linh Le, Joanne Wang, Greg Nicholson, Amy Brideau-Andersen, Lance Steward, Birgitte Jacky, Ron Broide, Mark Washburn, David Rupp

Safety and Tolerability of OnabotulinumtoxinA in the Treatment of Facial Lines: Statistical Meta-analysis of Pooled Data From Global Registration Studies of Treatment of Crow's Feet Lines and Glabellar Lines in More Than 3900 Participants

• Date and Time: Friday, March 3, 3:40-3:45 PM
• Location: E-Poster, Aesthetic Dermatology Section
• Authors: Jean Carruthers, Mitchell F. Brin, Koen De Boulle, Steven Liew, Alastair Carruthers, Alexander Rivkin, Yan Wu, Irina Yushmanova, Terry I. Boodhoo, Kathy Zhuang, Conor J. Gallagher, Elisabeth Lee

A comparison of self-reported signs of facial aging among women in Australia vs. those in the United States, United Kingdom & Canada

• Date and Time: Friday, March 3, 11:45-11:50 AM
• Location: E-Poster, Aesthetic Dermatology Section
• Authors: Greg J. Goodman, Katherine Armour, Julia Kolodziejczyk, Conor J. Gallagher

Characterization of the In Vivo Pharmacology of Oxymetazoline and Brimonidine Using a Mouse Model of UV-Induced Erythema

• Date and Time: Friday, March 3, 1:10-1:15 PM
• Location: E-Poster, Aesthetic Dermatology Section
• Authors: Edward Hsia, Mingting Tian, Daniel Gil

Efficacy and Safety of Topical Oxymetazoline Cream 1.0% for Treatment of Facial Erythema Associated With Rosacea: Findings From Two Phase 3, Pivotal Trials

• Date and Time: Friday, March 3, 1:45-1:50 PM
• Location: E-Poster, Aesthetic Dermatology Section
• Authors: Linda Stein-Gold, Leon H. Kircik, Zoe Diane Draelos, Philip Werschler, Janet DuBois, Edward Lain, Leslie Baumann, David J. Goldberg, Joely Kaufman, Emil A. Tanghetti, Emily Weng, David R. Berk, Gurpreet Ahluwalia

Patient-Rated Satisfaction Assessment for Rosacea Facial Redness (SAT-RFR): Results of Two Phase 3 Pivotal Trials of Oxymetazoline Cream 1% vs Vehicle

• Date and Time: Friday, March 3, 9:00-9:05 AM
• Location: E-Poster, Clinical Dermatology & Other Cutaneous Disorders Section
• Authors: Ilia L. Ferrusi, Gurpreet Ahluwalia, David A. Andrae

Patient-Rated Symptom Assessment for Rosacea Facial Redness (SA-RFR): Results of Two Phase 3 Pivotal Trials of Oxymetazoline Cream 1% vs Vehicle

• Date and Time: Friday, March 3, 9:05-9:10 AM
• Location: E-Poster, Clinical Dermatology & Other Cutaneous Disorders Section
• Authors: Ilia L. Ferrusi, Gurpreet Ahluwalia, David A. Andrae

Development and Validation of the Satisfaction Assessment for Rosacea Facial Redness (SAT-RFR)

• Date and Time: Friday, March 3, 1:25-1:30 PM
• Room: E-Poster, Clinical Dermatology & Other Cutaneous Disorders Section
• Authors: Ilia L. Ferrusi, Gurpreet Ahluwalia, David A. Andrae

Development and Validation of the Symptom Assessment for Rosacea Facial Redness (SA-RFR)

• Date and Time: Friday, March 3, 1:30-1:35 PM
• Location: E-Poster, Clinical Dermatology & Other Cutaneous Disorders Section
• Authors: Ilia L. Ferrusi, Gurpreet Ahluwalia, David A. Andrae

Efficacy and Safety of Topical Oxymetazoline Cream 1.0% for the Treatment of Facial Erythema Associated With Rosacea: Findings From 1 of 2 Pivotal Trials

• Date and Time: Friday, March 3, 2:20-2:25 PM
• Location: E-Poster, Clinical Dermatology & Other Cutaneous Disorders Section
• Authors: Leon H. Kircik, Janet DuBois, Zoe Diane Draelos, Philip Werschler, Kimberly Grande, Fran E. Cook-Bolden, David R. Berk, Gurpreet Ahluwalia

Efficacy and Safety of Topical Oxymetazoline Cream 1.0% for the Treatment of Facial Erythema Associated With Rosacea: Findings From the Second of 2 Pivotal Trials

• Date and Time: Friday, March 3, 2:25-2:30 PM
• Location: E-Poster, Clinical Dermatology & Other Cutaneous Disorders Section
• Authors: Leslie Baumann, David J. Goldberg, Linda Stein-Gold, Emil A. Tanghetti, Ted Lain, Joely Kaufman, David R. Berk, Gurpreet Ahluwalia

Long-term Safety and Efficacy of Topical Oxymetazoline Cream 1.0% for Treatment of Persistent Facial Erythema Associated With Rosacea

• Date and Time: Friday, March 3, 4:55-5:00 PM
• Location: E-Poster, Clinical Dermatology & Other Cutaneous Disorders Section
• Authors: Zoe Diana Draelos, Michael H. Gold, Robert A. Weiss, Leslie Baumann, Steven K. Grekin, Deanne Mraz Robinson, Steven E. Kempers, David R. Berk, Gurpreet Ahluwalia

Efficacy and Safety of Oral Sarecycline for the Treatment of Moderate to Severe Facial Acne Vulgaris: Results of a Phase 2, Dose-Ranging Trial

• Date and Time: Friday, March 3, 9:00-9:05 AM
• Location: E-Poster, Acne Section
• Authors: James J. Leyden, Vilma Sniukiene, David R. Berk, Alexandre Kaoukhov

Cosmetic Efficacy of a Comprehensive Serum for Facial Hyperpigmentation in Multiple Ethnic Populations

• Date and Time: Friday, March 3, 1:20-1:25 PM
• Location: E-Poster, Aesthetic Dermatology Section
• Authors: Elizabeth T. Makino, Priscilla Tan, Rahul C. Mehta

Efficacy of a Comprehensive Serum in Japanese Subjects with Moderate to Severe Facial Hyperpigmentation

• Date and Time: Friday, March 3, 1:50-1:55 PM
• Location: E-Poster, Aesthetic Dermatology
• Authors: Elizabeth T. Makino, Priscilla Tan, Rahul C. Mehta

Efficacy of a Comprehensive Serum in Thai Subjects with Moderate to Severe Facial Hyperpigmentation

• Date and Time: Friday, March 3,1:55-2:00 PM
• Location: E-Poster, Aesthetic Dermatology Section
• Authors: Elizabeth T. Makino, Priscilla Tan, Rahul C. Mehta

Rejuvenation in neck appearance from topical treatment with physiologically-balanced growth factors, antioxidants and sunscreen actives

• Date and Time: Friday, March 3, 3:25-3:30 PM
• Location: E-Poster, Aesthetic Dermatology Section
• Authors: Lisa T. Goberdhan, Elizabeth T. Makino, Rahul C. Mehta

Social Perceptions Before and After Treatment With ATX-101 (Deoxycholic Acid Injection) for Reduction of Submental Fat

• Date and Time: Friday, March 3, 4:05-4:10 PM
• Location: E-Poster, Aesthetic Dermatology Section
• Authors: Shannon Humphrey, Steven H. Dayan, Sachin M. Shridharani, Leslie Baumann, Conor J. Gallagher

Pan-facial Aesthetic Treatment Positively and Significantly Impacts Social Perception

• Date and Time: Saturday, March 4th from 1:00-3:00 PM
• Location: Late-Breaking Research Forum: Procedural Dermatology, Room W304C
• Authors: Steven H. Dayan, Alexander Rivkin, Jonathan M. Sykes, Craig F. Teller, Susan H. Weinkle, Garrett T. Shumate, Conor J. Gallagher

About Allergan plc

Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical company and a leader in a new industry model – Growth Pharma. Allergan is focused on developing, manufacturing and commercializing branded pharmaceuticals, devices and biologic products for patients around the world.

Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology and anti-infective therapeutic categories.

Allergan is an industry leader in Open Science, the Company's R&D model, which defines our approach to identifying and developing game-changing ideas and innovation for better patient care.  This approach has led to Allergan building one of the broadest development pipelines in the pharmaceutical industry with 70+ mid-to-late stage pipeline programs in development.

Our Company's success is powered by our more than 16,000 global colleagues' commitment to being Bold for Life.  Together, we build bridges, power ideas, act fast and drive results for our customers and patients around the world by always doing what is right.

With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day.

For more information, visit Allergan's website at www.Allergan.com.

Forward-Looking Statement

Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Allergan's current expectations depending upon a number of factors affecting Allergan's business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Annual Report on Form 10-K for the year ended December 31, 2015 and Quarterly Report on Form 10-Q for the quarter ended September 30, 2016 (certain of such periodic public filings having been filed under the "Actavis plc" name). Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.

© 2017 Allergan. All rights reserved. All trademarks are the property of their respective owners.

CONTACTS:                                     

Investors:
Lisa DeFrancesco
(862) 261-7152                                                                                                                 

Karina Calzadilla
(862) 261-7328

Media:
Mark Marmur
(862) 261-7558

Ember Garrett
(714) 246-3525

SOURCE Allergan plc

Related Links

http://www.allergan.com